The most serious adverse effect is [[bleeding]], including severe [[internal bleeding]].<ref>{{cite web |title= Medication Guide--Xarelto |url= http://www.fda.gov/downloads/Drugs/DrugSafety/UCM280333.pdf |publisher= U.S. Food and Drug Administration |accessdate= 1 September 2014}}</ref><ref>{{cite web |title= Xarelto Side Effects |url= http://www.webmd.com/drugs/2/drug-156265/xarelto-oral/details/list-sideeffects |publisher= WebMD |accessdate=1 September 2014}}</ref><ref>{{cite web |title=Xarelto Side Effects Center |url= http://www.rxlist.com/xarelto-side-effects-drug-center.htm |publisher= RxList |accessdate= 1 September 2014}}</ref> Rivaroxaban is associated with lower rates of serious and fatal bleeding events than warfarin but is associated with higher rates of bleeding in the [[gastrointestinal tract]].<ref name=Brown2015/> There is currently no antidote for rivaroxaban (unlike warfarin, the action of which can be reversed with [[vitamin K]] or [[prothrombin complex concentrate]]), meaning that serious bleeding may be difficult to manage.

 


 
In October 2014, Portola Pharmaceuticals completed Phase I and II clinical trials for [[andexanet alfa]] as an antidote for Factor Xa inhibitors with few adverse effects, and started Phase III trials.<ref>{{cite web |last1= Schroeder |first1=C. |title= Possible Antidote Could Help Blood Thinner Patients In Bleeding Emergencies |url= https://www.drugnews.net/news/antidote-xarelto-blood-thinner-patients-emergency/ |website= DrugNews |accessdate= 20 August 2015}}</ref><ref>{{cite journal |title= Recent advances in the development of specific antidotes for target-specific oral anticoagulants |vauthors= Mo Y, Yam FK |journal= Pharmacotherapy |date= Feb 2015 |volume=35 |issue=2 |pages=198–207 |doi= 10.1002/phar.1532 |pmid= 25644580}}</ref> Andexanet alfa was expected to be approved in 2016.<ref name="reuters">{{Cite web |url= https://www.reuters.com/article/us-pharmaceuticals-bloodthinners-idUSKBN0U617320151223 |title= New blood thinner 'antidote' to help doctors move past warfarin |last=Bill Berkrot  |date=December 23, 2015 |publisher=Reuters}}</ref>{{As of| 2017}}, the compound has yet to be approved by the U.S. Food and Drug Administration.

 


 
{{As of| 2015}}, post-marketing assessments showed liver toxicity, and further studies are needed to quantify the risk.<ref>{{Cite journal|title = Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system|journal = British Journal of Clinical Pharmacology|date = 2015-08-01|issn = 1365-2125|pmc = 4541976|pmid = 25689417|pages = 285–293|volume = 80|issue = 2|doi = 10.1111/bcp.12611|first = Emanuel|last = Raschi|first2 = Elisabetta|last2 = Poluzzi|first3 = Ariola|last3 = Koci|first4 = Francesco|last4 = Salvo|first5 = Antoine|last5 = Pariente|first6 = Maurizio|last6 = Biselli|first7 = Ugo|last7 = Moretti|first8 = Nicholas|last8 = Moore|first9 = Fabrizio|last9 = De Ponti}}</ref><ref>{{Cite journal|title = Rivaroxaban postmarketing risk of liver injury|journal = Journal of Hepatology|date = 2014-08-01|issn = 1600-0641|pmid = 24681117|pages = 293–300|volume = 61|issue = 2|doi = 10.1016/j.jhep.2014.03.026|first = Stefan|last = Russmann|first2 = David F.|last2 = Niedrig|first3 = Mathias|last3 = Budmiger|first4 = Caroline|last4 = Schmidt|first5 = Bruno|last5 = Stieger|first6 = Sandra|last6 = Hürlimann|first7 = Gerd A.|last7 = Kullak-Ublick}}</ref> The drug is contraindicated in people with significant liver disease and end-stage kidney disease, in whom the drug was not trialed.

 


 
Rivaroxaban has a [[boxed warning]] to make clear that people using the drug should not discontinue it before talking with their health care professional, because it can increase the risk of stroke.<ref name="fda-Xarelto-label">{{cite web|title = XARELTO (rivaroxaban) label|url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022406s015lbl.pdf|publisher=U.S. Food and Drug Association}}</ref>

 


 
In 2015, rivaroxaban accounted for the highest number of reported cases of serious injury among regularly monitored drugs to the FDA's Adverse Events Reporting System (AERS).<ref>{{cite web|last1=Schroeder|first1=C|title=ISMP Ranks Xarelto Most Dangerous Drug in the United States|url=https://www.drugnews.net/news/ismp-ranks-xarelto-most-dangerous-drug-in-US|website=DrugNews|publisher=DrugNews|accessdate=10 August 2016}}</ref>

 

